NEW YORK, July 10 – Molecular Devices has signed a definitive agreement to acquire Cytion, a Swiss developer of drug screening technology, for $7.5 million in cash and 400,000 shares of Molecular Devices stock, Molecular Devices said Tuesday.

Cytion, based in Epalinges, Switzerland, has developed a technique using automated patch clamping for analyzing ion channels, a class of proteins important as drug targets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.